Switzerland plays a key role in biotechnology in Europe. With its prominent pharmaceutical industry, the country has had many success stories in the field. The San Francisco Bay Area is fertile ground in the United States for biotechnology, home to Genentech and many other global companies. However, fundraising is becoming more and more difficult on both sides of the Atlantic.
While the “who’s who” of the biotech finance community is in San Francisco for the J.P. Morgan Healthcare Conference, we invite successful CEOs, entrepreneurs, representatives of the pharmaceutical industry, and investors to share strategies to attract capital. The event covers the latest trends and happenings in the two hotspots and fosters the exchange of ideas between Swiss and Bay Area counterparts, investors, and entrepreneurs in the life sciences industry. Join us for the chance to meet other industry players and discuss the important issues.
6:00 pm doors open 6:30 pm welcome by hosts 6:35 pm presentation 1: Comparison on European biotech locations – where does Switzerland stand? 6:50 pm presentation 2: BayArea – A successful regional entrepreneur 7:05 pm panel discussion: To be a successful entrepreneur in Switzerland/the Bay Area – or how to raise more money than you burn? 8:00 pm drinks and networking
Thomas Linder, Tax Director, KPMG AG
KPMG is a global network of professional firms providing audit, tax, and advisory services. We have 145,000 outstanding professionals working together to deliver value in 152 countries worldwide. In today’s global environment, life science companies often expand their businesses into new markets to remain competitive. Expansion can be sought for numerous business reasons, including mergers and acquisitions, new products, increased demand, an expanding customer base, cost refining, and many other factors. KPMG has a dedicated practice with broad technical expertise and deep industry knowledge in order to support life science companies with their global expansion and site selection projects.
Patrik Frei, CEO, Venture Valuation
Venture Valuation specializes in independent assessments and valuations of companies in high-growth markets, such as biotechnology, life sciences, and medical technology. Furthermore, the company manages and runs the global Biotechgate Database as a subscription service and a white label solution for organizations including BIOTECanada, BioCom San Diego, Swiss Stock Exchange SIX, Swiss Biotech, Biovalley, BioAlps, BIO.NRW, Medicon Valley, SwedenBIO, and more than 25 country databases.
Simon Meier, Investment Director, Roche Venture Fund
The Roche Venture Fund is the corporate venture fund of the healthcare company Roche. Roche has been investing in early stage companies as part of collaborations since the early 1990s and in independent of collaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund, which reports directly into the Roche Group CFO. In the past 20 years, the Roche Venture Fund has invested in more than 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America, and the Pacific Region. The fund is an evergreen fund with CHF 500 million available, of which approximately 40 percent is currently invested.
Simon Nebel, Managing Partner, Aravis
Founded in 2001 and located in Zurich, Aravis is the first independent, Swiss, on-shore private equity house. With a track record of investment in renewable energy and life science, Aravis is currently managing more than a quarter billion Swiss francs. Aravis’s funds have a track record of success in the service of more than 30 leading investors including corporate, pension funds, government funds, insurance companies, and family offices. Aravis has a cumulative history of investments in more than 100 companies. With a long track record in life sciences and two life science investment funds (ARAVIS Biotech I and ARAVIS Biotech II), Aravis has held an early stage stake in some of the more eye-catching Swiss life science companies.
Christian Zahnd, CEO, Molecular Partners AG
Molecular Partners is a privately owned biopharmaceutical company, located in Zurich, Switzerland, that is pioneering the development of a novel class of targeted protein therapeutics termed DARPins. Molecular Partners is backed by a very strong international syndicate of institutional and corporate investors. In August 2012, Molecular Partners announced the expansion of their existing relationship partnership with Allergan, Inc., whereby Molecular Partners has received an upfront payment of $62.5 million and is eligible to receive additional success-based payments, including up to $1.4 billion in aggregate development, regulatory, and sales milestones.
Gail Maderis, President and CEO, BayBio
BayBio is the industry organization representing and supporting Northern California’s life science community. As a former biotech CEO, Gail brings deep experience and commitment to supporting the industry through enterprise development, peer-to-peer experience sharing, advocacy, and support of education and workforce development. From 2003 to 2009, Gail served as president and CEO of Five Prime Therapeutics, Inc., a privately held protein discovery and development company. At Five Prime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials. Gail received a bachelor’s degree in business from UC Berkeley and a master’s in business administration from Harvard Business School.
Photo: Myleen Hollero